share_log

HC Wainwright & Co. Maintains Buy on KemPharm, Lowers Price Target to $10

Benzinga Real-time News ·  Aug 17, 2022 06:40

HC Wainwright & Co. analyst Oren Livnat maintains KemPharm (NASDAQ:KMPH) with a Buy and lowers the price target from $11 to $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment